[{"address1": "23 Old Bond Street", "address2": "Floor 3", "city": "London", "zip": "WIS 4PZ", "country": "United Kingdom", "website": "https://www.kiniksa.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1\u00df-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.", "fullTimeEmployees": 315, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sanj K. Patel", "age": 56, "title": "CEO & Chairman of the Board", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 1643910, "exercisedValue": 5193352, "unexercisedValue": 18032466}, {"maxAge": 1, "name": "Mr. Mark A. Ragosa C.F.A.", "age": 51, "title": "Senior VP & CFO", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 800778, "exercisedValue": 845501, "unexercisedValue": 1154320}, {"maxAge": 1, "name": "Mr. Ross Michael Moat", "age": 45, "title": "COO & Principal Operating Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 809776, "exercisedValue": 1039097, "unexercisedValue": 780631}, {"maxAge": 1, "name": "Dr. John F. Paolini FACC, M.D., Ph.D.", "age": 60, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 893755, "exercisedValue": 2579261, "unexercisedValue": 4298211}, {"maxAge": 1, "name": "Mr. Eben  Tessari", "age": 43, "title": "Chief Strategy Officer", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 818644, "exercisedValue": 1249727, "unexercisedValue": 3791178}, {"maxAge": 1, "name": "Mr. Michael R. Megna CPA", "age": 54, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mei  Jang", "title": "Senior VP & Chief Technical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Jonathan  Kirshenbaum", "title": "Investor Relations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Barry", "title": "Senior VP, Chief Legal Officer & Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan  Woods M.B.A.", "title": "Senior VP & Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 47.17, "open": 47.46, "dayLow": 46.75, "dayHigh": 47.855, "regularMarketPreviousClose": 47.17, "regularMarketOpen": 47.46, "regularMarketDayLow": 46.75, "regularMarketDayHigh": 47.855, "payoutRatio": 0.0, "beta": 0.054, "trailingPE": 106.155556, "forwardPE": 26.480043, "volume": 436766, "regularMarketVolume": 436766, "averageVolume": 502926, "averageVolume10days": 395350, "averageDailyVolume10Day": 395350, "bid": 47.56, "ask": 47.85, "bidSize": 1, "askSize": 1, "marketCap": 3620763392, "fiftyTwoWeekLow": 18.255, "fiftyTwoWeekHigh": 47.855, "allTimeHigh": 46.65, "allTimeLow": 5.01, "priceToSalesTrailing12Months": 6.055062, "fiftyDayAverage": 42.2209, "twoHundredDayAverage": 35.436176, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3278379520, "profitMargins": 0.06007, "floatShares": 39183376, "sharesOutstanding": 45161019, "sharesShort": 3064527, "sharesShortPriorMonth": 3570712, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0404, "heldPercentInsiders": 0.03972, "heldPercentInstitutions": 0.97431, "shortRatio": 4.42, "shortPercentOfFloat": 0.0734, "impliedSharesOutstanding": 75795759, "bookValue": 7.098, "priceToBook": 6.730065, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": 35918000, "trailingEps": 0.45, "forwardEps": 1.804, "enterpriseToRevenue": 5.482, "enterpriseToEbitda": 82.702, "52WeekChange": 1.3207161, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 47.77, "targetHighPrice": 62.0, "targetLowPrice": 50.0, "targetMeanPrice": 55.875, "targetMedianPrice": 56.5, "recommendationMean": 1.125, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 352102016, "totalCashPerShare": 4.645, "ebitda": 39641000, "totalDebt": 9718000, "quickRatio": 3.268, "currentRatio": 3.848, "totalRevenue": 597972992, "debtToEquity": 1.815, "revenuePerShare": 8.159, "returnOnAssets": 0.03762, "returnOnEquity": 0.07388, "grossProfits": 315644992, "freeCashflow": 50336248, "operatingCashflow": 102861000, "revenueGrowth": 0.612, "grossMargins": 0.52786, "ebitdaMargins": 0.06629, "operatingMargins": 0.13282, "financialCurrency": "USD", "symbol": "KNSA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1771625376, "regularMarketTime": 1771621203, "exchange": "NMS", "messageBoardId": "finmb_558211765", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.272, "regularMarketPrice": 47.77, "shortName": "Kiniksa Pharmaceuticals Interna", "longName": "Kiniksa Pharmaceuticals International, plc", "earningsTimestamp": 1771939800, "earningsTimestampStart": 1771939800, "earningsTimestampEnd": 1771939800, "earningsCallTimestampStart": 1771939800, "earningsCallTimestampEnd": 1771939800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.45, "epsForward": 1.804, "epsCurrentYear": 1.062, "priceEpsCurrentYear": 44.981167, "fiftyDayAverageChange": 5.549099, "fiftyDayAverageChangePercent": 0.13143013, "twoHundredDayAverageChange": 12.333824, "twoHundredDayAverageChangePercent": 0.34805742, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Kiniksa Pharmaceuticals, Ltd.", "nameChangeDate": "2026-02-21", "averageAnalystRating": "1.1 - Strong Buy", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1527255000000, "postMarketChangePercent": 0.0, "postMarketPrice": 47.77, "postMarketChange": 0.0, "regularMarketChange": 0.600002, "regularMarketDayRange": "46.75 - 47.855", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 502926, "fiftyTwoWeekLowChange": 29.515001, "fiftyTwoWeekLowChangePercent": 1.6168175, "fiftyTwoWeekRange": "18.255 - 47.855", "fiftyTwoWeekHighChange": -0.084999084, "fiftyTwoWeekHighChangePercent": -0.0017761798, "fiftyTwoWeekChangePercent": 132.07161, "displayName": "Kiniksa Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]